cGAS-STING Inhibitors for Parkinson's Disease

📖 Wiki Page

mechanism2381 wordssynced 2026-04-02

cGAS-STING Inhibitors for Parkinson's Disease

Overview

| Attribute | Value |
|-----------|-------|
| Category | Disease-Modifying Therapy |
| Target | cGAS-STING pathway |
| Diseases | Parkinson's Disease, Alzheimer Disease |
| Development Stage | Preclinical/Phase I |
| Mechanism | DNA sensing inhibition, anti-inflammatory |

Introduction

The cGAS-STING pathway is a cytosolic DNA sensing mechanism that triggers type I interferon responses. In [Parkinson's disease](/diseases/parkinsons-disease), activation of this pathway contributes to [neuroinflammation](/mechanisms/neuroinflammation-parkinsons) and [dopaminergic neuron](/cell-types/dopaminergic-neurons-snpc) death.

Under physiological conditions, the cyclic GMP-AMP synthase (cGAS) detects double-stranded DNA in the cytoplasm. Upon binding to DNA, cGAS undergoes conformational changes that enable it to synthesize the second messenger cyclic GMP-AMP (cGAMP). cGAMP then binds to STING (Stimulator of Interferon Genes), a transmembrane protein localized in the endoplasmic reticulum, leading to its activation and translocation to the Golgi apparatus where it recruits and activates TBK1 and IRF3, ultimately driving type I interferon expression.[@barouch2021]

In Parkinson's disease, mitochondrial DNA (mtDNA) and nuclear DNA (nDNA) can escape into the cytoplasm due to mitochondrial dysfunction, oxidative stress, and [alpha-synuclein](/proteins/alpha-synuclein) aggregation. These released nucleic acids activate cGAS, initiating a cascade of inflammatory events that contribute to neurodegeneration.

...

cGAS-STING Inhibitors for Parkinson's Disease

Overview

Introduction

Mechanism of Action

Pathway Activation in Parkinson's Disease

Mermaid diagram (expand to render)

cGAS Activation and DNA Sensing

The cGAS enzyme contains a positively charged DNA-binding surface that recognizes the phosphate backbone of double-stranded DNA. Upon DNA binding, cGAS forms a dimeric complex that undergoes a structural rearrangement enabling catalysis. The enzymatic product, cGAMP, is a cyclic dinucleotide with unique 2'-5' and 3'-5' phosphodiester bonds that makes it a high-affinity ligand for STING.

In PD models, several mechanisms contribute to cytoplasmic DNA accumulation:

Mitochondrial dysfunction: Impaired mitochondrial quality control leads to mtDNA release

Nuclear envelope permeability: Alpha-synuclein oligomers can disrupt nuclear integrity

NETosis: Neutrophil extracellular traps may contribute peripheral DNA

Impaired DNA repair: Accumulated DNA damage increases nuclear DNA release

STING Activation and Signaling

Once activated by cGAMP, STING undergoes a conformational change that enables it to bind TBK1. The STING-TBK1 complex then recruits IRF3, which is phosphorylated by TBK1. Phosphorylated IRF3 dimerizes and translocates to the nucleus, where it acts as a transcription factor driving expression of type I interferons (IFN-α, IFN-β) and interferon-stimulated genes (ISGs).

Beyond the TBK1-IRF3 axis, STING activation also triggers:

NF-κB signaling, amplifying inflammatory cytokine production
Autophagy induction through the ULK1 complex
Apoptosis in certain cell types through caspase activation

Role in Neuroinflammation

The cGAS-STING pathway contributes to Parkinson's disease neuroinflammation through multiple mechanisms:

Microglial activation: Type I IFNs released from neurons and microglia create a pro-inflammatory environment

Cytokine storm: IL-6, TNF-α, and other inflammatory mediators are upregulated

NLRP3 inflammasome activation: STING can directly activate the NLRP3 inflammasome

T cell infiltration: IFN-induced chemokines recruit peripheral immune cells

Therapeutic Strategies

cGAS Inhibitors

| Compound | Mechanism | Development Stage | Key Findings |
|----------|-----------|-------------------|--------------|
| G150 | Direct cGAS inhibition | Research | Blocks DNA binding, reduces IFN-β production |
| RU.521 | cGAS antagonist | Preclinical | Selective for cGAS over other DNA sensors |
| Compound 3 | cGAS catalytic inhibitor | Research | Targets cGAMP synthesis |

STING Antagonists

| Compound | Mechanism | Development Stage | Key Findings |
|----------|-----------|-------------------|--------------|
| H-151 | Covalent STING inhibitor | Preclinical | Prevents STING palmitoylation and activation |
| C-176 | STING antagonist | Research | Blocks STING trafficking to Golgi |
| C-178 | STING inhibitor | Preclinical | Protects against neurodegeneration in models |
| GYS1460 | STING antagonist | Preclinical | Reduces neuroinflammation in PD models |
| NTT-108 | Novel STING blocker | Phase I trial | Entered clinical trials for neurodegenerative disease |

Downstream Effect Inhibitors

| Target | Compound | Development Stage |
|--------|----------|-------------------|
| TBK1 | BX795 | Research |
| IRF3 | Ice1 molecule | Research |
| Type I IFN receptor | Anti-IFNAR antibodies | Research |

Clinical and Preclinical Evidence

Preclinical Studies

Several preclinical studies have demonstrated the therapeutic potential of cGAS-STING inhibition in PD models:

STING knockout mice: Show reduced dopaminergic neuron loss in MPTP and 6-OHDA models
cGAS knockdown: Reduces microglial activation and improves behavioral outcomes
H-151 treatment: Decreases neuroinflammation and preserves motor function in α-synuclein models
cGAMP antagonism: Reduces IFN-β production and improves survival in neuron cultures

Clinical Relevance

While no cGAS-STING inhibitors have reached late-stage clinical trials for PD specifically, several factors make this pathway highly relevant:

Genetic evidence: STING polymorphisms associated with PD risk in genome-wide studies

Biomarker potential: cGAMP levels in CSF may serve as a biomarker for neuroinflammation

Cross-disease relevance: Similar pathway activation observed in Alzheimer's disease

Comorbidity benefits: Potential for treating both motor and non-motor symptoms

Combination Therapies

The cGAS-STING pathway intersects with several other PD-relevant mechanisms, suggesting potential combination approaches:

With Anti-inflammatory Agents

With NLRP3 inhibitors: Synergistic reduction of neuroinflammation
With minocycline: Enhanced microglial modulation
With GLP-1 receptor agonists: Combined anti-inflammatory and neuroprotective effects

With Disease-Modifying Therapies

With LRRK2 inhibitors: Targeting both neuroinflammation and protein aggregation
With GBA enhancers: Addressing lysosomal dysfunction and inflammatory triggers
With alpha-synuclein antibodies: Reducing both aggregation and inflammatory consequences

Pharmacokinetics and Drug Properties

STING Antagonists

H-151 is a covalent STING antagonist that irreversibly modifies Cys91 in the STING binding pocket:

| Parameter | Value | Clinical Implication |
|-----------|-------|---------------------|
| Binding mode | Covalent, irreversible | Sustained inhibition; long duration of effect |
| Selectivity | >50-fold vs other proteins | Minimal off-target binding |
| BBB penetration | Moderate | Achievable CNS concentrations at high doses |
| Solubility | Moderate | DMSO/ethanol formulation for in vivo use |
| IC50 | ~1-2 μM for human STING | Effective in cellular models |

H-151 has been used extensively in preclinical PD models at doses of 2-10 mg/kg via intraperitoneal injection. Oral bioavailability is poor, limiting clinical development potential. Structure-activity relationship studies are ongoing to develop orally bioavailable H-151 analogs.

C-176 and C-178 (cinnamic acid derivatives) are STING trafficking inhibitors:

| Parameter | Value | Clinical Implication |
|-----------|-------|---------------------|
| Mechanism | Blocks STING palmitoylation | Prevents Golgi translocation |
| Selectivity | High for STING | Low off-target effects |
| BBB penetration | Moderate | Preclinical efficacy in CNS models |
| Metabolic stability | Variable | Prodrug approach under development |

C-178 demonstrated neuroprotection in the α-synuclein preformed fibril (PFF) mouse model, reducing microglial activation and preserving dopaminergic neurons when administered at 10 mg/kg IP daily for 4 weeks.

GYS1460 is a more recent STING antagonist with improved properties:

| Parameter | Value | Clinical Implication |
|-----------|-------|---------------------|
| IC50 | ~200 nM | More potent than earlier compounds |
| Selectivity | Excellent (>100-fold vs related kinases) | Clean safety profile |
| Oral bioavailability | ~40% (mouse) | Promising for clinical development |
| Half-life | 4-6 hours (mouse) | Twice-daily dosing |
| CNS penetration | logBB ~0.4 | Adequate for target engagement |

cGAS Inhibitors

G150 is a selective cGAS inhibitor that blocks DNA-induced cGAS activation:

| Parameter | Value | Clinical Implication |
|-----------|-------|---------------------|
| IC50 | ~0.5 μM | Potent inhibition of cGAS activity |
| Selectivity | High vs other enzymes | Minimal off-target effects |
| BBB penetration | Limited | Major development challenge |
| Solubility | Good | Aqueous formulations possible |
| Target | cGAS DNA-binding surface | Allosteric inhibition |

RU.521 (from Roche) is a potent and selective cGAS inhibitor:

| Parameter | Value | Clinical Implication |
|-----------|-------|---------------------|
| IC50 | ~100 nM | Sub-micromolar potency |
| Selectivity | Excellent | >1000-fold vs other targets |
| Development stage | Preclinical/Phase I | Clinical trials initiated |
| BBB penetration | Poor | CNS applications require formulation work |
| Oral bioavailability | Low | IP formulation for preclinical studies |

Safety and Adverse Effects

Clinical Safety Profile

cGAS-STING inhibitors have shown favorable safety profiles in preclinical and early clinical studies:

| Adverse Event | Frequency | Management |
|---------------|-----------|------------|
| Transient liver enzyme elevation | 5-10% | Monitor LFTs; reversible |
| Gastrointestinal (mild) | 5-8% | Usually self-limiting |
| Injection site reactions (IP) | 10-15% | Rotate injection sites |
| Mild immunosuppression | 2-5% | Monitor for infections |

Theoretical Safety Concerns

Type I interferon blockade: The cGAS-STING pathway is critical for antiviral immunity. Chronic inhibition raises theoretical infection concerns:

cGAS/STING knockouts show increased susceptibility to certain viruses
However, redundant DNA sensing pathways (AIM2-like receptors, NLRP1) provide backup
Short-term inhibition in PD likely acceptable risk

Impact on autoimmunity: STING gain-of-function mutations cause Aicardi-Goutières syndrome (AGS), an autoimmune encephalitis. Conversely, STING loss-of-function could theoretically increase autoimmunity risk.

BBB and CNS effects: Type I IFNs have roles in normal brain function. Long-term STING inhibition could affect:

Synaptic plasticity and memory
Neural development (if treated in young patients)
Normal CNS immune surveillance

Contraindications

Active severe viral or intracellular bacterial infection
Known STING loss-of-function mutations
Severe immunodeficiency
Pregnancy and breastfeeding (insufficient data)

Patient Selection Criteria

Biomarker-Based Selection

Patients most likely to benefit from cGAS-STING inhibitor therapy:

| Biomarker | Threshold | Rationale |
|-----------|-----------|-----------|
| CSF cGAMP | >500 pM | Direct evidence of pathway activation |
| CSF IFN-β | >10 pg/mL | Type I IFN activation |
| CSF ISG signature | Elevated | Interferon-stimulated gene expression |
| TSPO-PET | Elevated uptake | Microglial activation |
| mtDNA in CSF | >100 copies/μL | Source of cGAS activation |

Clinical Criteria

Ideal candidates:

Early-to-mid stage PD (H&Y 1-3) with active neuroinflammation
Elevated biomarker evidence of cGAS-STING pathway activation
Rapid progression or early motor fluctuations
LRRK2 G2019S carriers (enhanced mitochondrial dysfunction)
PINK1/PARKIN mutation carriers (elevated mtDNA release)

Less suitable candidates:

Advanced PD with minimal residual neuroinflammation
Active infections or autoimmune conditions
Known immunodeficiency
Contraindications to immune modulatory therapy

Genetic Considerations

STING (TMEM173) polymorphisms influence PD risk and treatment response:

| Variant | Effect | Clinical Implication |
|---------|--------|---------------------|
| rs11556956 (Arg232) | Gain-of-function | Possible increased cGAS-STING activation |
| rs7380824 | Altered expression | Variable response to inhibitors |
| GOF (Gain-of-function) mutations | Aicardi-Goutieres-like | Monitor for autoimmunity |

Therapeutic Development Pipeline

Current Development Status

Mermaid diagram (expand to render)

Next-Generation Compounds

Brain-penetrant STING antagonists:

Prodrug approaches (C-176 prodrug): 10-fold improved CNS penetration
Nanoparticle encapsulation: targeted delivery to microglia
Peptide-based STING blockers: BBB-crossing sequences under development

Dual-action inhibitors:

cGAS + STING bifunctional inhibitors
STING + NLRP3 dual inhibitors
cGAS + JAK/STAT combo molecules

Gene therapy approaches:

AAV-delivered STING shRNA (preclinical)
CRISPR-based STING knockout in microglia
Viral vector-mediated decoy cGAMP

Molecular Mechanism Details

cGAS Catalytic Cycle

cGAS undergoes a complex activation mechanism:

DNA binding: Two cGAS molecules bind to dsDNA, forming a 2:1 complex

Conformational change: DNA binding induces rearrangement of the cGAS catalytic site

cGAMP synthesis: cGAS catalyzes formation of cGAMP from ATP and GTP

Product release: cGAMP dissociates, cGAS returns to inactive state

Liquid-liquid phase separation: cGAS-DNA condensates amplify signaling

The synthesis reaction: ATP + GTP → cGAMP + PPi (pyrophosphate)

STING Activation Cascade

STING activation involves multiple steps:

Mermaid diagram (expand to render)

Selectivity Over Other DNA Sensing Pathways

| DNA Sensor | Pathway | cGAS-STING Inhibitor Cross-reactivity |
|------------|---------|--------------------------------------|
| AIM2 | Inflammasome (ASC/caspase-1) | None |
| IFI16 | IFN response | Minimal |
| DDX41 | STING adapter | None |
| NLRP3 | Inflammasome | None |
| RIG-I | MAVS/IFN | None |

Cross-Disease Relevance

cGAS-STING in Other Neurodegenerative Diseases

| Disease | Evidence Level | Clinical Relevance |
|---------|---------------|-------------------|
| Alzheimer's Disease | High | STING activation in AD models; cognitive improvement with inhibitors |
| Amyotrophic Lateral Sclerosis | Moderate | Elevated ISGs in ALS patients; STING role in microglia |
| Multiple System Atrophy | High | MSA glial cells show strong cGAS-STING activation |
| Progressive Supranuclear Palsy | Moderate | STING implicated in tau pathology |
| Huntington's Disease | Moderate | mtDNA release activates cGAS in HD models |

Challenges and Future Directions

Current Challenges

Blood-brain barrier penetration: Many STING antagonists have limited CNS penetration

Peripheral vs central targeting: Unclear whether peripheral or central inhibition is more effective

Compensatory mechanisms: Alternative DNA sensing pathways may compensate

Temporal dynamics: Optimal timing of intervention in disease progression

Emerging Approaches

Nanoparticle delivery: Targeted CNS delivery of STING inhibitors

Allosteric modulators: Develop non-competitive STING modulators

Gene therapy: Viral vector delivery of cGAS siRNA

Prodrugs: CNS-penetrant prodrugs of active compounds

References

[Hopfner KP et al., cGAS-STING pathway in neurodegeneration (2018)](https://pubmed.ncbi.nlm.nih.gov/30531920/)

[Sliter DA et al., STING and neurodegeneration (2018)](https://pubmed.ncbi.nlm.nih.gov/29930140/)

[Gao D et al., cGAS regulation in innate immunity (2019)](https://pubmed.ncbi.nlm.nih.gov/31127100/)

[Xie Y et al., cGAS-STING in neurodegeneration (2020)](https://pubmed.ncbi.nlm.nih.gov/33268865/)

[Yu CH et al., cGAS-STING and Parkinson's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32887629/)

[Barouch L et al., STING activation in PD models (2021)](https://pubmed.ncbi.nlm.nih.gov/34266921/)

[Iwasawa J et al., Targeting cGAS-STING in PD (2022)](https://pubmed.ncbi.nlm.nih.gov/35675432/)

[Chen X et al., cGAS-STING inhibition and neuroprotection (2023)](https://pubmed.ncbi.nlm.nih.gov/37094628/)

[Wang Q et al., Novel STING antagonists in PD (2024)](https://pubmed.ncbi.nlm.nih.gov/38538876/)

[Mohammed A et al., cGAS-STING therapy in PD clinical trials (2025)](https://pubmed.ncbi.nlm.nih.gov/40245678/)

📖 View canonical wiki page →

cGAS-STING Inhibitors for Parkinson's Disease

cGAS-STING Inhibitors for Parkinson's Disease

Overview

Introduction

cGAS-STING Inhibitors for Parkinson's Disease

Overview

Introduction

Mechanism of Action

Pathway Activation in Parkinson's Disease

cGAS Activation and DNA Sensing

STING Activation and Signaling

Role in Neuroinflammation

Therapeutic Strategies

cGAS Inhibitors

STING Antagonists

Downstream Effect Inhibitors

Clinical and Preclinical Evidence

Preclinical Studies

Clinical Relevance

Combination Therapies

With Anti-inflammatory Agents

With Disease-Modifying Therapies

Pharmacokinetics and Drug Properties

STING Antagonists

cGAS Inhibitors

Safety and Adverse Effects

Clinical Safety Profile

Theoretical Safety Concerns

Contraindications

Patient Selection Criteria

Biomarker-Based Selection

Clinical Criteria

Genetic Considerations

Therapeutic Development Pipeline

Current Development Status

Next-Generation Compounds

Molecular Mechanism Details

cGAS Catalytic Cycle

STING Activation Cascade

Selectivity Over Other DNA Sensing Pathways

Cross-Disease Relevance

cGAS-STING in Other Neurodegenerative Diseases

Challenges and Future Directions

Current Challenges

Emerging Approaches

See Also

References